Why Exact Sciences Shares Rallied 10.2% in August
After the company reported better-than-expected top- and bottom-line second-quarter results in late July and updated investors on its strategy at Cannacord's 37th annual growth conference on Aug. 9, shares of Exact Sciences (NASDAQ: EXAS) jumped 10.2% last month, according to S&P Global Market Intelligence.
Guidelines call for everyone between ages 50 to 74 to be on a colon cancer screening "schedule," yet millions of Americans are failing to follow through on being tested, and as a result, more cases of late-stage colon cancer are being diagnosed than there should be.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Exact Sciences Stock
€41.73
-4.920%
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Exact Sciences.
With a target price of 77 € there is a hugely positive potential of 84.52% for Exact Sciences compared to the current price of 41.73 €.
